AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Stephen Heuser
Dec. 15--Alnylam Pharmaceuticals Inc., a Cambridge biotechnology company, said it will start development next year on a treatment for pandemic flu, funded partly by a grant from the US Department of Defense.
The treatment would use a new technique, RNA interference, in which short strands of genetic material are custom-built to shut down flu virus genes.
The company has developed several possible RNAi drugs that have stopped flu viruses from reproducing themselves in a test tube, chief executive John Maraganore said yesterday, and plans to apply to start human testing on one or two substances in the second half of 2006.…